No experience
Employment Type:
Job Category:
Intern, Cell Metabolism
(This job is no longer available)
Agios Pharmaceuticals | Cambridge, MA
Grad Date

Not sure what types of jobs you are interested in?

Explore Jobs
Based on Your Education

Follow This Company

Job Description

Intern, Cell Metabolism

Agios Pharmaceuticals is searching for an enthusiastic and determined biochemist to join the Cell Metabolism team. The successful summer intern will pursue novel drug combinations that target cancer metabolism and perform mechanistic studies using mass spectrometry. The intern will have the opportunity to utilize a variety of molecular biology and analytical techniques, while gaining exposure to the drug development process.

Key Responsibilities

* Perform cell-based assays to assess the impact of small molecule inhibitors on metabolism and cancer cell growth

* Participate in the design, execution, and analysis of mechanistic studies utilizing mass spectrometry and stable-isotope tracing

* Maintain good written records of procedures, results, and conclusions

* Present results and conclusions in a variety of settings

Minimum Requirements

* The intern should have a bachelor's degree in biology, chemistry, or a related field

* Tissue culture proficiency and good aseptic technique are required

* The intern should demonstrate the ability to think critically and creatively

Preferred Qualifications

* Experience performing small molecule assays in a medium-throughput format is a plus

* Theoretical knowledge or experience in mass spectrometry

* Curiosity for metabolism

About Agios Pharmaceuticals

Agios is an independent, private biopharmaceutical company at the forefront of drug discovery in one of the most exciting new areas of cancer research: cancer metabolism. The intersection of two fields of research - cancer and metabolism - offers an important and novel approach to treating cancer. Research in cancer metabolism has provided new understandings of fundamental mechanisms behind cancer survival, representing a new, powerful strategy to target this deadly disease. Agios is developing a diverse pipeline of cancer metabolism drug candidates, building on the company's intellectual property and drug discovery platform as well as the unique insights of its founders and scientific advisors. Agios' novel drugs will be targeted therapies directed at modulating key metabolic pathways such as glycolysis (sugar metabolism), fatty acid metabolism, and autophagy (self-metabolism). The company's primary focus is in oncology, though Agios' platform may also be applicable to other therapeutics areas featuring diseases of cellular proliferation, including autoimmune, inflammatory and neurological diseases. Agios has a scientific team that is second to none in the field of cancer metabolism. The company was founded by the core thought leaders who have made key advances and discoveries in the field of cancer metabolism. Agios has attracted and continues to seek out top talent to translate the science of cancer metabolism into transformational drugs for patients.